Eli Lilly Eli Lilly and Company (LLY) today September 17, announced positive topline results from ACHIEVE-3, Phase 3 clinical trial evaluating the safety and efficacy of orforglipron compared to oral semaglutide, administered according to approved label instructions in 1,698 adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial compared orforglipron (12 mg and 36 mg) to oral . . . This content is …

Jazz Pharmaceuticals On September 9, 2025, Jazz Pharmaceuticals plc (JAZZ) announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A single-agent treatment option for pediatric and adult patients with recurrent or progressive diffuse high-grade glioma harboring an H3 K27M mutation. Modeyso was granted . . . This content is for paid subscribers. Please …

Xenon Pharmaceuticals A Company  Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated to drug discovery, development, and commercialization of life-changing therapeutics for patients in need, announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 55,300 share options. Xenon’s lead molecule, azetukalner, azetukalner -  a novel, potent, selective Kv7 potassium channel opener in Phase . . . …

Alnylam Pharmaceuticals Press Release Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering …

Regeneron Pharmaceuticals Announcement Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months. Regeneron Pharmaceuticals, Inc. (REGN . . . This content …

Alkermes in the NEWS Today, Alkermes Inc., (ALKS) announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, (formerly ALKS 2680), is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1, narcolepsy type 2 . . . This content is for paid subscribers. Please …

Ionis Pharmaceuticals in the NEWS Today, Sep. 2, 2025, Ionis Pharmaceuticals (IONS) announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In the studies, olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a highly statistically significant reduction in acute . . . This content …

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The presentations will be webcast, providing company updates for investors.   Investor Conference Presentations  Citi's 2025 Biopharma Back to School Conference:  Alnylam management will present an overview of the company on Wednesday, September 3, 2025. Morgan Stanley 23rd Annual Global Healthcare Conference: A presentation is also scheduled for Monday, September . …

Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has approved updated versions of the COVID-19 vaccines from Pfizer, Moderna and Novavax.  These updated shots are intended to better protect against currently circulating variants. The 2024–2025 formulations of the following vaccines are approved for certain groups: Pfizer (

BioArtic AB & Novartis Sign Agreement Stockholm, Sweden, August 26, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG (

One bad market day or more can help investors make it a good biotech market day. On the bad market days, many star firms become way undervalued for no reason whatsoever. Instead of selling these stocks Prohost's motto is to buy more. On Another Topic Prohost decided to buy NTLA. Recently this company's stocks started moving up, including yesterday, a bad market day.  We selected …

Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced  that the U.S. FDA has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory . . . This content is for paid …

Rhythm Pharmaceuticals in the NEWS Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. FDA has accepted for filing the company’s supplemental New Drug Application (sNDA) for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA

Precigen in the NEWS Precigen (PGEN) announced that the United States (FDA) has approved the product  PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. Precigen completed submission of the rolling Biologics License Application (BLA) in December 2024 . . . This content is for paid subscribers. Please click here …

Insmed Incorporated Today, investors must have realized the upward movement prices of the Viking Therapeutics (VKTX) and Intellia Therapeutics (NTLA . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Boehringer Ingelheim The following is not for investors but for people who love pets and want them to be healthy and live longer. Those who care about animals should know what’s going on in the highly regarded veterinary research and practice, and the next generation of biomedical researchers. Recently, a posted text informed that Boehringer Ingelheim has celebrated the next generation of biomedical researchers at …

Akero Therapeutics Akero Therapeutics (AKRO) reported its Q22025 financial results for the period ending June 30, 2025 as well as providing a business update. The report was published from the 96-Week Phase 2b SYMMETRY trial published in the New England Journal of Medicine. Three presentations highlighted data demonstrating statistically significant reversal of MASH compensated cirrhosis, and the anti-fibrotic activity . . . This content is …

Gilead Sciences Reached Prohost Biotech's Target Gilead Sciences (GILD) reached our target of $120 today. Some investors will sell some and keep some and other investors will sell all the stocks they have. We will keep our stocks as we are increasing the target. Yesterday was Gilead's announcement of its second Quarter 2025 financials. The following is what . . . This content is for …

Praxis Precision Medicines in the NEWS  On Aug. 04, 2025, the biopharmaceutical company Praxis Precision Medicines (PRAX), translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance provided a corporate update and reported financial results for the second quarter 2025. From Praxis Precision Medicines “In the second quarter, we continued to make remarkable progress across our portfolio …

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results and More  Today, July 31, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of . . . This content …